Cue Biopharma vs Arcus Biosciences
CUE and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CUE and RCUS compare
Arcus Biosciences is the larger company, worth 18 times as much as Cue Biopharma ($2.4B against $136M).
Cue Biopharma grew revenue faster over the last twelve months (354% versus −58.3% for Arcus Biosciences).
Cue Biopharma keeps more of each dollar of sales as profit, with a net margin of −436% compared with −453% at Arcus Biosciences.
Cue Biopharma scores higher on the StockData Score (8 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CUE | RCUS |
|---|---|---|
| Size and price | ||
| Market cap | $136M | $2.4B |
| Share price | $18.66 | $18.80 |
| Change, 1 year | −8.7% | −3.4% |
| Change, 5 years | −95.8% | −60.5% |
| Beta (5Y) | 2.37 | 1.43 |
| Employees | 29 | 601 |
| StockData Score | ||
| Total score | 8 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.6× (better) | 23.9× |
| P/B | 58.7× | 6.7× (better) |
| FCF yield | −37.0% | −19.5% (better) |
| Fair value | – | $5.97 |
| Margin of safety | – | −215% |
| Growth | ||
| Revenue growth (TTM) | 354% (better) | −58.3% |
| Revenue growth, 5Y average | 54.2% (better) | 25.9% |
| Profitability | ||
| Operating margin | −262% (better) | −475% |
| Net margin | −436% (better) | −453% |
| FCF margin | −133% (better) | −466% |
| Return on equity | −1603% | −114% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −43.2× |
| Current ratio | 1.25 | 3.34 (better) |
| Altman Z-score | −30.32 | −1.12 (better) |
| Piotroski F-score | 5 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −11.7% |
| Shareholder yield | 0.00% (better) | −11.7% |
| Ownership | ||
| Held by institutions | 22.6% | 96.3% |
| Held by insiders | 17.4% | 31.7% |
| Insider net buying, 12 months | −$2.3M (better) | −$9.3M |
| Short interest, % of float | 14.4% | 15.2% |
Go deeper
- CUE stock overview
- CUE income statement
- CUE valuation and score
- RCUS stock overview
- RCUS income statement
- RCUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.